The effect of insomnia on mild cognitive impairment in patients with vascular risks: results of a three-year longitudinal study

Vorobeva O.V.; Shindryaeva N.N.; Fateeva V.V.

doi:https://doi.org/10.17116/jnevro202412403230

Vorobeva O.V.

Chuvash state university named after I.N. Ulyanov

SPIN RSCI: 5084-1379
ORCID: 0000-0003-3259-3691

Shindryaeva N.N.

Sechenov First Moscow State Medical University (Sechenov University);
City Clinic No. 2

ORCID: 0000-0001-6560-2756

Fateeva V.V.

Federal scientific and clinical center for resuscitation and rehabilitology;
Pirogov Russian National Research Medical University

ORCID: 0000-0001-9935-3962

The effect of insomnia on mild cognitive impairment in patients with vascular risks: results of a three-year longitudinal study

Authors:

Vorobeva O.V., Shindryaeva N.N., Fateeva V.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(3‑2): 30‑36

DOI: 10.17116/jnevro202412403230

Read: 1640 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Vorobeva OV, Shindryaeva NN, Fateeva VV. The effect of insomnia on mild cognitive impairment in patients with vascular risks: results of a three-year longitudinal study. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(3‑2):30‑36. (In Russ.)
https://doi.org/10.17116/jnevro202412403230

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

To assess the dynamics of sleep parameters based on the analysis of three items of HDRS-17, designed to measure the severity of insomnia, during 36 months of follow-up and their relationship with indicators of the cognitive phenotype in patients with vascular risk factors.

MATERIAL AND METHODS

The longitudinal study included 51 patients (mean age 57.7±6.2 years, 19 (37.3%) men)) who met the inclusion criteria. All participants underwent a general clinical examination with assessment of vascular risks and neuropsychological testing using the Montreal Cognitive Assessment (MoCA) and HDRS-17 at baseline and after 36 months. During the study, patients received stable basic therapy to prevent modifiable vascular risk factors. Sleeping pills were taken sporadically when there were complaints of problems falling asleep.

RESULTS

During the 36-month study, as vascular cognitive impairment progressed from 23.7±2.6 to 22.1±2.4 points on the MoCA scale (p=0.01), mainly due to decreased attention (p=0.01), executive functions (EF) (p=0.01), memory (p=0.02), speech (p=0.02), an increase in sleep disturbances was observed (item 4: 0.8±0.02 to 1.9±0.1 points, p=0.01; point 5: 0.6±0.02 to 1.7±0.1 points, p=0.01) and depression (7.5±0.5 to 13.7±3.0 points, p=0.01) in patients with vascular risks. A strong inverse correlation was revealed between the values of items 4, 5, 6 on the HDRS-17 and the average MoCA-total scores (r=–0.85; r=–0.87; r=–0.8 (p<0.05)), memory index (r=–0.8; r=–0.75; r=–0.81 (p<0.05)), attention index (r=–0.88; r=–0.86; r=–0.83 (p<0.05)), index of executive functions (r=–0.87; r=–0.85; r=–0.8 (p<0.05)), respectively.

CONCLUSION

The progression of cognitive impairment is associated with worsening insomnia disorders and depression in patients with vascular risks.

Keywords:

insomnia

cognitive impairment

depression

vascular risk factors

Authors:

Vorobeva O.V.

Chuvash state university named after I.N. Ulyanov

SPIN RSCI: 5084-1379
ORCID: 0000-0003-3259-3691

Shindryaeva N.N.

Sechenov First Moscow State Medical University (Sechenov University);
City Clinic No. 2

ORCID: 0000-0001-6560-2756

Fateeva V.V.

Federal scientific and clinical center for resuscitation and rehabilitology;
Pirogov Russian National Research Medical University

ORCID: 0000-0001-9935-3962

Received:

27.11.2023

Accepted:

30.11.2023

Close metadata

References:

Poluektov MG, Buzunov RV, Averbukh VM. Draft clinical guidelines for the diagnosis and treatment of chronic insomnia in adults. Consilium Medicum. Neurology and Rheumatology (Add.). 2016;2:41-51. (In Russ.).
Poluektov MG. Sleep and cognitive function. Effective Pharmacotherapy. Neurology and Psychiatry. 2018;20(3):20-27. (In Russ.).
Bochkarev MV, Korostovtseva LS, Filchenko IA, et al. Social-demographic aspects of insomnia in the Russian population according to ESSE-RF study. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2018;118(4-2):26-34. (In Russ.). https://doi.org/10.17116/jnevro20181184226
Vorobyova O.V. Sleep disturbances in cerebrovascular disease, approaches to correction. Attending Doctor. 2016;10:23-28. (In Russ.).
Dobrynina LA, Gadzhieva ZSh, Shamtieva KV, et al. Predictors and integrative index of severity of cognitive disorders in cerebral microangiopathy. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2022;122(4):52-60. (In Russ.). https://doi.org/10.17116/jnevro202212204152
Vorobyova OV. Cerebral microangiopathy associated with age and/or arterial hypertension (clinical and pathogenetic aspects, approaches to therapy). Pharmateka. 2019;26(9):92-97. (In Russ.). https://doi.org/10.18565/pharmateca.2019.9.77-82
Jiang B, Ding C, Yao G. Polysomnographic abnormalities in patients with vascular cognitive impairment-no dementia. Sleep Med. 2013;14(11):1071-1075. https://doi.org/10.1016/j.sleep.2013.07.003
Jackson ML, Howard ME, Barnes M. Cognition and daytime functioning in sleep-related breathing disorders. Prog Brain Res. 2011;190:53-68. https://doi.org/10.1016/b978-0-444-53817-8.00003-7
Vorobyova O.V. Treatment of depression associated with cerebrovascular disease (according to the Russian multicenter naturalistic study «RESONANCE»). Doctor. 2012;12:26-29. (In Russ.).
Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery, And Psychiatry. 1960;23(1):56-62. https://doi.org/10.1136/jnnp.23.1.56
Wardlaw JM, Smith EE, Biessels GJ, et al. STandards for ReportIng Vascular changes on nEuroimaging (STRIVE v1). Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12(8):822-838. https://doi.org/10.1016/S1474-4422(13)70124-8
Julayanont P, Brousseau M, Chertkow H, et al. Montreal Cognitive Assessment Memory Index Score (MoCA-MIS) as a predictor of conversion from mild cognitive impairment to Alzheimer’s disease. J Am Geriatr Soc. 2014;62(4):679-684. https://doi.org/10.1111/jgs.12742
Lo JC, Groeger JA, Cheng GH, et al. Self-reported sleep duration and cognitive performance in older adults: a systematic review and meta-analysis. Sleep Med. 2016;17:87-98. https://doi.org/10.1016/j.sleep.2015.08.021
Javaheri S, Redline S. Insomnia and risk of cardiovascular disease. Chest. 2017;152(2):435-444. https://doi.org/10.1016/j.chest.2017.01.026
Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr. 2006;83(2):456S-460S. https://doi.org/10.1093/ajcn/83.2.456s
Shearer WT, Reuben JM, Mullington JM. Soluble TNF-α receptor 1 and IL-6 plasma levels in humans subjected to the sleep deprivation model of spaceflight. J Allergy Clin Immunol. 2001;107(1):165-170. https://doi.org/10.1067/mai.2001.112270
Fateeva VV, Vorob’eva OV. Cerebral markers of endothelial dysfunction in chronic brain ischemia. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2017;117(4):107-111. (In Russ.). https://doi.org/10.17116/jnevro201711741107-111
Vorobyova OV, Nikulina KV, Fateeva VV. The relationship between oxidative stress and mild cognitive impairment in patients with cerebral atherosclerosis: results of a prospective cohort study. Effective Pharmacotherapy. 2022;18(23):12-18. (In Russ.).